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Yong Chen 1 ✉

Linear mixed models are commonly used in healthcare-based association analyses for analyzing multi-site data with heterogeneous site-speciﬁc random effects. Due to regulations for
protecting patients’ privacy, sensitive individual patient data (IPD) typically cannot be shared
across sites. We propose an algorithm for ﬁtting distributed linear mixed models (DLMMs)
without sharing IPD across sites. This algorithm achieves results identical to those achieved
using pooled IPD from multiple sites (i.e., the same effect size and standard error estimates),
hence demonstrating the lossless property. The algorithm requires each site to contribute
minimal aggregated data in only one round of communication. We demonstrate the lossless
property of the proposed DLMM algorithm by investigating the associations between
demographic and clinical characteristics and length of hospital stay in COVID-19 patients
using administrative claims from the UnitedHealth Group Clinical Discovery Database.
We extend this association study by incorporating 120,609 COVID-19 patients from 11
collaborative data sources worldwide.
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I

ntegrating data from multiple sites can increase statistical
power and generalizability1. The recent development of clinical research networks (CRNs) have established networks of
researchers and databases for multi-site, large-scale analyses2. For
example, in the United States, the National Patient-Centered
Clinical Research Network (PCORnet) is a large, highly representative electronic data infrastructure, covering 337 hospitals
with data from 80 million patients3–5. PCORnet was established a
decade ago to improve comparative effectiveness research,
patient-centered outcome research, and pragmatic trials. The
international Observational Health Data Sciences and Informatics
(OHDSI) network6 has accumulated more than half a billion
patient records from 19 different countries worldwide, with
around 300 million patient records within the United States.
Other research networks include the ACT Network (Accrual to
Clinical Trials)7, the Food and Drug Administration’s Sentinel
Initiative8, and TriNetX9, among others. In response to the
COVID-19 pandemic, there have been great efforts to build
national COVID cohorts and improve data infrastructure10.
Signiﬁcant examples include the National COVID Cohort Collaborative (N3C) and the Consortium for Characterization of
COVID-19 by EHR (4CE), which is an international consortium
of 96 hospitals across ﬁve countries11.
Research networks are vital for advancing clinical research and
responding to the COVID-19 crisis. For example, Burn et al.12
analyzed the characteristics of adults hospitalized with COVID19 and compared them with inﬂuenza patients based on the
OHDSI network. However, while multi-site studies via CRNs are
promising, they present several key challenges. First, most CRNs
convert their data to a common data model (CDM) while
retaining the data at their individual clinical sites. Sensitive
individual patient data (IPD) including patient demographics,
diagnoses, and treatments usually cannot be shared across networks under privacy regulations such as the Health Insurance
Portability and Accountability Act (HIPAA) in the United States
or the General Data Protection Regulation (GDPR) in the E.U.
The second challenge is the requirement of iterative communications in the existing federated/distributed learning
framework13,14. Although these federated learning algorithms
allow modeling on distributed datasets without sharing patientlevel data, they typically require iterative processes, resulting in
multiple communications among data contributors that add
effort and delay. Implementation of these algorithms usually
requires extra computation infrastructures across networks15 to
allow iterative communications of model parameter estimates.
Thirdly, the data from across sites are often heterogeneous due to
difference in patient characteristics and other site-level variations.
Ignoring this heterogeneity could lead to biased estimates and
misleading predictions from the analyses.
Pooled analysis

•
•
•
•

NOT privacy-protected
NOT communication-efficient
Heterogeneity-aware
Highly accurate

The above challenges add to the timely responses to the
COVID-19 and other time sensitive research. To address these
challenges, we propose an algorithm for performing distributed
linear mixed models (DLMMs) when integrating data from
multiple sites. The linear mixed model (LMM) is an extension of
the linear model and allows for modeling site-speciﬁc effects of
covariates on the outcome. The LMM assumes site-speciﬁc random effects in addition to common ﬁxed effects. Random effects
help us quantify the systematic deviations, e.g., administrative
differences across sites, from the overall population-level effects
which are characterized by the common ﬁxed effects. The estimation of common ﬁxed effects enables general knowledge discovery, while the estimation of random effects allows
quantiﬁcation of between-site heterogeneity and site-speciﬁc
predictions.
Computation of the LMM requires maximizing the proﬁle
likelihood16, whose calculation cannot be distributed to different
sites using the traditional technique of matrix decomposition17,18.
Regular federated learning algorithms13,14,19 require the iterative
transmission of aggregated data (AD) and therefore are not
communication efﬁcient. Instead, our proposed algorithm
requires each site to contribute AD only once, but achieves
identical results (i.e., identical effect size and standard error
estimates) as the analysis from the pooled IPD data. This DLMM
algorithm has four properties:
1. Privacy-preserving: Only requires sharing of AD
2. Communication-efﬁcient: Only requires one round of
communication
3. Heterogeneity-aware: Allows for site-speciﬁc effects
4. Lossless: Achieves identical results (i.e., identical effect size
and standard error estimates) as the analysis from the
pooled IPD data
See Fig. 1 for a comparison of the existing and the proposed
approaches for analyzing multi-site data. We note that, generally,
an algorithm being lossless has to sacriﬁce certain properties of
the algorithm, such as the privacy protection or communicationefﬁciency. However, there are rare exceptions algorithms can be
both lossless and privacy-protected. One such example is the
lossless distributed algorithm for linear regression18, being lossless, communication-efﬁcient and privacy-protected. Our proposed algorithm inherits such unique property of the distributed
linear regression for being both lossless and privacy-preserving,
yet being able to account for between-site heterogeneity.
In this paper, we use the length of stay (LOS) of hospitalized
COVID-19 patients as an illustrating example. LOS has a direct
implication on hospital capacity, as a commonly used and easily
measured indicator of inpatient health care utilization. LOS is an
important outcome for the evaluation of clinical interventions20.
The proposed
DLMM algorithm

Meta-analysis

•
•
•
•

Privacy-protected
Communication-efficient
Heterogeneity-aware
Not highly accurate

•
•
•
•

Privacy-protected
Communication-efficient
Heterogeneity-aware
Highly accurate (lossless)

Fig. 1 Comparison of approaches for multi-site analysis with heterogeneity across sites. Pooled analysis: data analysis based on the pooled individual
patient data; Meta-analysis: statistical analysis by combining the effect size and standard error estimates from different sites; The proposed DLMM
algorithm: the distributed linear mixed model algorithm.
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Identifying factors associated with variation in LOS can lead to a
better understanding of how to improve clinical care and economic efﬁciency. In addition, LOS is an ideal outcome in our
illustration to study heterogeneous outcomes in real world data.
For example, Rees and colleagues21 found that the LOS of
COVID-19 hospitalization in China is longer than in other
countries, possibly because China has stricter discharge criteria.
When studying the association between LOS and such patient
characteristics as age, gender, Charlson Comorbidity Index (CCI),
and history of cancer, heart disease, hypertension, hyperlipidemia, and diabetes, the impact of these variables on the LOS of
COVID-19 hospitalization may differ across sites22, representing
a common situation of heterogeneity in not only the baseline (i.e.,
the mean LOS across different sites), but also the associations
between these risk factors and the LOS outcome.
In the Results section, we ﬁrst formulate the LMM and the
proposed DLMM algorithm, and then validate the above properties of the DLMM algorithm using data from the UnitedHealth
Group Clinical Discovery Portal. We analyze the pooled data
from 538 hospitals using regular LMM and compare these results
with those from the DLMM algorithm applied to the same data
without allowing IPD sharing. We then apply the DLMM algorithm to analyze the association between LOS of COVID-19
hospitalization with patients’ demographic, admission, and clinical characteristics using the electronic health records (EHR) and
claims from 11 databases across three countries (US, Spain, and
South Korea) with a total of 120,609 COVID-19 patients.
Results
Distributed linear mixed model and the lossless property.
Linear mixed models with site-level random effects can be used to
account for the heterogeneous effects of covariates on a continuous outcome. Assume for the jth patient at the ith site, yij is
the continuous outcome, xij is the p-dimensional covariate vector,
β is the vector of ﬁxed effects, zij is the q-dimensional covariate
vector, ui is the q-dimensional random effect, and ϵij is the random error.
yij ¼ xij T β þ z ij ui þ ϵij ; i ¼ 1; :::; K; j ¼ 1; :::; ni ;

ð1Þ

where ui  Nð0; VÞ; ϵij  Nð0; σ Þ. The random effects covariates
zij can be part or all of xij , or constant 1 if representing a random
intercept only. The random effect covariance matrix V can have
certain structures with unknown parameters. For instance, we can
assume the random effects are independent, i.e.,
V ¼ diagðσ 1 2 ; :::; σ q 2 Þ. These parameters (e.g., variance components) and the ﬁxed effects β are usually estimated by maximum
likelihood (ML) or restricted maximum likelihood (REML)
estimation17.
For the scenario in which IPD data are distributed at multiple
sites and pooling is restricted, we have developed a distributed
algorithm to ﬁt the LMM in a privacy-preserving and
communication-efﬁcient manner. Figure 2 demonstrates how
the proposed DLMM algorithm works. The algorithm requires
only aggregated data Si X ¼ X i T X i ; Si Xy ¼ X i T yi ; si y ¼ yi T yi and
sample size ni from the ith site to reconstruct the likelihood for
ﬁtting the model. Notice the communication of aggregated data is
required only once, and the reconstructed likelihood leads to
identical results compared to the pooled analysis that requires
IPD from all sites. See the Methods Section for more details of the
algorithm.
We demonstrate the utility and lossless property of the DLMM
method by studying the association of COVID-19 hospitalization
LOS with patients’ demographic and clinical characteristics, using
the medical claims data from the UnitedHealth Group (UHG)
2
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Fig. 2 Schematic overview of the proposed algorithm for distributed
linear mixed model (DLMM). The linear mixed model takes into account
the heterogeneity of the effect of the covariates X (e.g., patients’
characteristics) on the continuous outcome y (e.g., COVID-19
hospitalization length of stay) across sites. The proposed distributed
algorithm achieves identical results as pooling the individual patient data
(IPD) from all sites, by requiring only aggregated data (AD) Si X ; Si Xy ; si y and
sample size ni from the ith site. The DLMM algorithm does not depend on a
“leading site” and any site can conduct the analysis given the aggregated
data are available.

Clinical Discovery Portal. Since we can access all the patient-level
data, comparing the results of pooled analysis and distributed
analysis can demonstrate the lossless property of the proposed
method. We identiﬁed patients who were admitted as inpatients
to a hospital with a primary diagnosis of COVID-19 between
January 1, 2020 and September 30, 2020. The data were collected
from K ¼ 538 sites (i.e., hospitals) and the total number of
patients is N ¼ ∑538
i¼1 ni ¼ 47; 756: The detailed inclusion criteria
are in the Supplementary Figs. 1 and 2. LOS was treated as a
continuous outcome. The variation in LOS across the sites is
shown in Fig. 3a. The demographic characteristics include age,
gender, and race, and the clinical characteristics include a history
of cancer, chronic obstructive pulmonary disease (COPD), heart
disease, hypertension, hyperlipidemia, diabetes, kidney disease,
and obesity. CCI score is also included as a measure of the overall
patient’s health state; the higher the score, the worse the health
state is. We provide the details of the deﬁnition of the
characteristics in the Supplementary Table 1.
We compare the result of the pooled analysis and the
distributed algorithm in Fig. 3. Speciﬁcally, the estimation of
the ﬁxed effects, their standard errors, and the variance
components are shown to be identical by the pooled analysis or
the distributed algorithm. The random effects of obesity, diabetes,
kidney disease, and CCI categories are signiﬁcant. The estimated
best linear unbiased predictors (BLUPs) (where “best” refers to
the minimal variance of the estimate among all the unbiased
linear estimates) of the random effects and their variances are
presented in the Supplementary Fig. 3, comparing the pooled
analysis and the distributed algorithm.
Figure 4 shows the forest plots of ﬁxed effects estimation and
BLUPs of the random effects at a speciﬁc site. Older age ( ≥ 80),
male gender, and diagnosis of diabetes, kidney disease, or obesity,
as well as higher CCI, are shown to be signiﬁcantly associated
with longer COVID-19 hospitalization. Non-Hispanic white
(NHW) race, cancer, and hyperlipidemia are signiﬁcantly
associated with shorter COVID-19 hospitalization. These results
agree with previous ﬁndings21,23–25.
International COVID-19 hospital LOS study. We further
demonstrated the applicability of the proposed DLMM algorithm
by investigating the association of COVID-19 hospitalization LOS
with patient characteristics, using the EHR and medical claims
data from 11 data sources within and outside of the United States.
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Fig. 3 The lossless property of the DLMM algorithm illustrated by the COVID-19 LOS study using the UHG data. a The mean and standard deviation of
length of stay of 47,756 hospitalized COVID-19 patients from 538 hospitals. The data were collected from a single large U.S. insurer via the UHG Clinical
Discovery Portal and are separated into their respective hospital sites to illustrate the algorithm. The area of each dot is proportional to the number of
patients at that hospital, and the color represents the region. b Fixed effects estimation of linear mixed model by the proposed DLMM algorithm vs. the
pooled analysis. c Fixed effects’ standard error estimation of linear mixed model by the proposed DLMM algorithm vs. the pooled analysis. d Variance
components estimation of linear mixed model by the proposed DLMM algorithm vs. the pooled analysis.

These data sources are shown in Fig. 5. The detailed description is
in the Supplementary Notes.
We categorize the UHG Clinical Discovery Portal data as four
“sites” based on geographical area, i.e., Northeast (UHG.NE),
South (UHG.S), West (UHG.W) and Midwest (UHG.MW). The
number of sites is thus K ¼ 14; and the total number of patients
is N ¼ ∑Ki¼1 ni ¼ 120; 609: The detailed inclusion and exclusion
criteria are in the Supplementary Notes. In addition to the
demographic and clinical characteristics deﬁned previously, we
also included the admission date (categorized as Q1, Q2, or Q3,
i.e., admission in the ﬁrst, second, or third quarter of 2020,
respectively). Race is excluded from the covariates, since race
information is missing from some data sources. A data summary
of the collaborative sites is in Supplementary Tables 3 and 4.
The random effects of all covariates are forward selected by the
likelihood ratio test. All covariates except obesity are tested as
having signiﬁcant random effects (see Supplementary Table S4).
The results of the estimated ﬁxed effects and prediction (i.e.,
estimated BLUPs) of the site-speciﬁc random effects are
presented in Figs. 6 and 7.
Below are the risk factors with signiﬁcant ﬁxed effects (p-value
< 0.001), as shown in Fig. 6.
●

●

4

Age and gender are signiﬁcant risk factors for increased
LOS. Age [65, 80) is associated with 0.96 days (95%
CI = 0.44–1.48) longer LOS, compared to age [18, 65); and
male gender is associated with 0.58 days (95%
CI = 0.24–0.92) longer LOS, compared to female gender.
CCI is a signiﬁcant risk factor for LOS. CCI [2,5) and 5+
are associated with 1.42 days (95% CI = 0.58–2.27) and
2.68 days (95% CI = 1.16–4.21) longer LOS respectively,
compared to CCI [0, 2).

●

●

Hospitalizations in the later time intervals are associated
with shorter LOS. Hospitalizations in the second and third
quarter are associated with 3.79 (95% CI = 3.03–4.55) and
6.26 (95% CI = 5.23–7.30) days shorter LOS, compared to
the ﬁrst quarter.
Among those comorbidity conditions, obesity is a signiﬁcant risk factor of LOS, associates with 0.37 (95%
CI = 0.21–0.52) days longer LOS.

Regarding the site-speciﬁc random effects, below are comparisons among sites, as shown in Fig. 7. Compared to other sites,
●

●

●
●

●

The baseline LOS (i.e., the intercept) is longer in in HIRA
COVID, and shorter in SIDIAP.
Age 80+ is associated with shorter LOS in CUIMC, and age
65-80 and male gender are associated with longer LOS
in CCAE.
Higher CCI score is associated with longer LOS in CUIMC.
CUIMC and Optum EHR have larger effects of admission
in the second quarter (i.e., longer LOS compared to the ﬁrst
quarter), and UHG.NE has smaller effects of admission in
the second and third quarter.
History of COPD, kidney and heart diseases are associated
with longer LOS in Optum COVID, and history of
hypertension, heart disease and diabetes are associated
with shorter LOS in CUIMC.

Discussion
Special care must be taken with health data in order to preserve
patient privacy. Anonymizing data while preserving features that
are important for understanding an individual’s health is nontrivial. In addition, large, representative datasets are especially
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Fig. 4 Distributed linear mixed model estimation of the COVID-19 LOS study using the UHG data. The UnitedHealth Group (UHG) Clinical Discovery
Portal medical claims data contains n = 47,756 independent patients from 538 sites (i.e., hospitals). a Fixed effects of demographic and clinical
characteristics on COVID-19 hospitalization length of stay. A vertical reference line is drawn for convenience in comparison. Reported are the estimated
effect sizes and 95% conﬁdence intervals. b BLUPs and 95% prediction intervals for random effects corresponding to a site located in the south region. The
95% conﬁdence (or prediction) intervals are presented as point estimate ±1.96 * standard error estimate. The corresponding p-values are based on twosided Wald tests.

scarce. Distributed models deal with the privacy issue by
requiring that only summary level statistics are shared. The oneshot model presented here requires only the aggregated data of a
p ´ p matrix, p-dimensional vector, and sample size be sent once,
where p is the number of risk factors in the association analysis.
This allows the data to remain completely protected by eliminating the need for data pooling at a central source. By considering a large, more diverse sample from multiple sites, we
expect a more robust estimation, which beneﬁts general knowledge discovery26,27. While we use the COVID-19 hospitalization
LOS study as an illustrative example, this distributed linear mixed
model algorithm can be applied to any continuous outcome
where potential heterogeneity exists for the effects of covariates
across sites.
Studying LOS heterogeneity across sites could help understand
and potentially predict future LOS, which is instrumental for
relieving the burden of healthcare systems during the pandemic
resurgence. In light of this, we are designing an online portal for
further collaboration. As the pandemic continues, more hospitalization data may be collected from additional countries/areas.
Therefore, it is important to update the association study in a
timely manner. With this online portal, any data source can
contribute aggregated data to update the estimation, and more
importantly, get a prediction of the site-speciﬁc effects of the
characteristics on COVID-19 LOS.
As suggested by a reviewer, the linear mixed model is closely
connected with the (random-effects) meta-analysis, as they both

assume the association effects are random and can shrink sitespeciﬁc (or study-speciﬁc) estimation which beneﬁts prediction
performance. A comparison of our LMM (or equivalently
DLMM) and the random-effects meta-analysis for the LOS study
is demonstrated in Supplementary Fig. 5. The results show that
the estimation of common ﬁxed-effects and site-speciﬁc random
effects (i.e., BLUPs) are similar but not identical. However, such
difference depends on various factors, such as the number of
patients per site, the ratio between the within-site heterogeneity
and the between-site heterogeneity, and the number of sites.
Meta-analysis-based model aggregation is extensively studied in
the literature for prediction purposes28–30. A comprehensive
comparison between LMM and meta-analysis is however beyond
the scope of this paper. We also note that in the setting of
modeling interactions, caution should be taken in the formulation
of the regression model in LMM. Through various proposed
formulations that distinguish between-study information from
the within-study information31,32, the aggregation bias can be
avoided.
Our DLMM algorithm is considered privacy-preserving as it
only requires one-shot communication of aggregated data from
collaborative sites, and the aggregated data are only shared within
collaborators who participate in the study. However, our aggregated data release mechanism has not been rigorously studied to
meet privacy-preserving criteria such as k-anonymity or differential privacy33–35. Speciﬁcally, the k-anonymity property protects against the risk of re-identiﬁcation33, which arises from
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Fig. 5 Map of the international data sources of the LOS for COVID-19 hospitalization. The headquarters of data sources are marked. The CUIMC,
STARR, OneFlorida, and TRDW cover parts of New York, California, Florida, and Massachusetts. The UHG, OHDSI (CCAE, MDCR, Optum EHR), and
Optum COVID cover multiple states in the United States. The SIDIAP and HIRA COVID cover Spain-Catalonia and South Korea, respectively. The circle
size represents data set size.

Fig. 6 The estimated ﬁxed effects and 95% conﬁdence intervals in the COVID-19 LOS study. The dashed and black CIs are the results using only the 4
UHG sites (the UHG database contains n = 47,756 patients and is divided into four sites, i.e., Northeast, South, Midwest, and West), the solid and red CIs
are the results using all 14 sites with n = 120,609 patients. The results are obtained by using the DLMM algorithm to integrate aggregated data from the
multiple sites. The 95% CIs are presented as point estimate ±1.96 * standard error estimate. The corresponding p-values are based on two-sided
Wald tests.
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Fig. 7 The estimated site-speciﬁc effects and 95% prediction intervals in the COVID-19 hospitalization LOS study. The study uses n = 120,609 patients
from the 14 sites. The site-speciﬁc effect is deﬁned as ﬁxed effect plus random effect, and a 95% prediction interval is point estimate ±1.96 * standard error
estimate.

linking potential quasi-identiﬁers (i.e., combinations of patient’s
characteristics in our study) to external sources33. In DLMM
aggregated data, if all the cell counts are not sparse, the algorithm
can potentially meet the k-anonymity requirement. In future
collaborations using DLMM, we suggest data contributors review
the aggregated data to avoid sparse cells (e.g., no cell count less
than 5) before sending them to other sites. We will quantify the
risk of privacy leaking more rigorously, and enhance our DLMM
algorithm via techniques such as differential privacy and multiparty homomorphic encryption36 in the future. On the other
hand, when reporting the estimated BLUPs for site-speciﬁc random effects, caution must be exercised if there is sensitive
information speciﬁc to sites that could be inferred from the result.
We thus suggest the estimated BLUPs not be disclosed if the
covariates are sensitive characteristics and write this in the protocol when initiating a collaborative project using the DLMM
algorithm in the future. Also, the privacy regulation of releasing
aggregated data could vary across countries and data providers.
The disclosure of aggregated data in the DLMM algorithm needs
to meet the local privacy requirement.
While we are able to integrate data sets from many sites, it is
possible that some data sets overlap with one another. For
example, the data from STARR/CUIMC/SIDIAP/HIRA COVID

are independent, yet data in the UHG Clinical Discovery Portal
cover all patients from a single large insurance provider across
multiple states and could overlap with other datasets, e.g., CCAE,
MDCR, and Optum COVID. As these other datasets include all
patients regardless of insurance provider, we estimate a 14%
overlap of the UHG data, consistent with their market share.
Moreover, while all collaborative sites are able to contribute
aggregated data from a common data model, it is difﬁcult to
obtain data of equal quality from all sites. For example, due to
data recording limitations, missing values exist for some factors
(e.g., race) at some sites, e.g., UHG, CCAE, MDCR, and SIDIAP.
Although we deﬁned the clinical conditions consistently (e.g.,
using the OHDSI common data model), the diagnosis of clinical
conditions in medical claims and EHR data from various systems
and countries are not necessarily consistent. Speciﬁcally, the
diagnosis of COVID-19 in UHG claims data is based on primary
or secondary diagnosis, with 90-95% of patients have a primary
diagnosis of COVID-19 at the time admission. However, in the
OHDSI network, not every data partner has primary/secondary
diagnosis speciﬁed in their data, thus another deﬁnition was
adopted, see the Appendix for details. In addition, some clinical
risk factors that could be associated with LOS (e.g., CT scan,
fever, and onset time22) are unavailable from EHR or claims data.
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Death is also poorly captured in some databases (e.g., CCAE,
MDCR, and HIRA COVID) and should therefore not be ruled
out as a competing risk.
We treated LOS as a continuous outcome, mainly for the
purpose of illustrating the proposed distributed algorithm. It
would be more reasonable to model LOS as a count outcome via
the generalized linear mixed model (GLMM) framework, e.g.,
Poisson regression with mixed effects, to account for the betweensite heterogeneity. Other important outcomes, such as mortality,
can also be modeled within the GLMM framework. While
GLMM is used in applications such as hospital proﬁling using
multi-center data37, there are few distributed algorithms for
privacy-preserving estimation. This is partially because the estimation of GLMM is computationally intensive and its likelihood
function is analytically intractable. One strategy of developing
distributed algorithms for GLMM is to use the penalized quasi
likelihood38 which can be built upon our DLMM algorithm; see
our dPQL algorithm and its application to hospital proﬁling
without sharing patient-level data39. Regarding scalability, our
DLMM algorithm has great scalability in terms of large number
of sites and large number of patients per site. However, in the
presence of high dimensional features (i.e., large p), the current
algorithm will require sharing of p ´ p dimensional matrices,
which may be too large to be transferred across sites due to
privacy concerns. As a result, studies that involve a large number
of predictors/features (e.g., a large-scale genomic study) are not
suitable for the proposed method. Extension of DLMM algorithm
to improve the scalability on large number of features remains an
important area for future research. Lastly, federated learning
methods have gained a great deal of attention in many clinical
settings in recent years40. We also consider the proposed method
as one variation of federated learning based on a speciﬁc statistical model, i.e., LMM. The LMM holds the promise of ﬂexibility
and interpretability of regression coefﬁcients, which are particularly suitable for epidemiological studies. Traditional federated
learning models have a focus on prediction, whilst the LMM
model in our analyses of LOS outcome focused on quantifying
associations of risk factors, which is commonly used in biomedical researches. In the future, we plan to investigate
communication-efﬁcient federated learning algorithms in distributed research network settings, which is a much-needed area
for new methods.
Methods
The multi-site COVID-19 hospitalization LOS data sets. Data were extracted
and included in the study if the patient had an inpatient visit between January 2020
and September 2020 satisfying
–
–
–
–

Age 18 years or older.
A COVID-19 diagnosis or positive test recorded up to 21 days prior to the
visit or during the visit.
Been active in the database for 6 months or more prior to the
inpatient visit.
Did not have a discharge status of “expired” prior to September 30, 2020.

A project protocol was created to implement the study https://github.com/
ohdsi-studies/DistributedLMM. In total 11 databases participated in the study and
shared the aggregated data results. The description and IRB approval or waiver are
listed below. The written informed consents for all the data were waived by the
corresponding IRBs.
The UHG data: A database of medical claims and hospitalizations from a
national claims data warehouse in the United States. Because no identiﬁable
protected health information was extracted or accessed during the course of the
study, and all data were accessed in compliance with the HIPPA rules, IRB
approval or waiver of authorization was not required. The ofﬁcial exemption by the
UHG IRB is also available.
The OneFlorida data: A CRN that contains robust and longitudinal patient-level
linked EHR and claims data from ~15 million Floridians from 12 unique healthcare
organizations. At OneFlorida, the access to the HIPAA Limited Data Set was
reviewed by the University of Florida Institutional Review Board under
8

IRB202001831. The analysis was run locally at the University of Florida and only
summary statistics were shared.
The Stanford Medicine Research Data Repository (STARR): An EHR database
of approximately three million patients from Stanford Hospitals and Clinics and
the Lucile Packard Children’s Hospital in the United States. The analysis had
institutional review board approval for using de-identiﬁed data, and thus was
determined not to be human subjects research and informed consent was not
deemed necessary.
Columbia University Irving Medical Center Data Warehouse (CUIMC):
Columbia University EHR database contains records from hospitals in New York
City. The analysis had institutional review board approval for using de-identiﬁed
data, and thus was determined not to be human subjects research and informed
consent was not deemed necessary.
IBM MarketScan Commercial Database (CCAE): A database of health
insurance claims from large employers and health plans who provide private
healthcare coverage to employees, their spouses, and dependents in the United
States. The patients are younger than 65. The aggregated data was reviewed by the
New England Institutional Review Board (IRB) and were determined to be exempt
from broad IRB approval, as this research project did not involve human subject
research.
IBM MarketScan Medicare Supplemental Database (MDCR): A database of
health insurance claims representing retirees (aged 65 or older) in the United States
with primary or Medicare supplemental coverage through privately insured fee-forservice, point-of-service, or capitated health plans. The aggregated data was
reviewed by the New England Institutional Review Board (IRB) and were
determined to be exempt from broad IRB approval, as this research project did not
involve human subject research.
Optum de-identiﬁed Electronic Health Record Dataset (Optum EHR): A
database of electronic healthcare records for patients in the United States. The
aggregated data was reviewed by the New England Institutional Review Board
(IRB) and were determined to be exempt from broad IRB approval, as this research
project did not involve human subject research.
Optum COVID data: The data are sourced from Optum’s longitudinal EHR
repository derived from more than 700 hospitals and 7000 clinics, including
patients who have documented clinical care from January 2007 through to the most
current monthly data release with a documented diagnosis of COVID-19 or acute
respiratory illness after February 1, 2020 and/or documented COVID-19 testing.
This dataset is fully de-identiﬁed and research using this dataset is not qualiﬁed as
human subject research per UTHealth IRB.
Tufts Medical Center Research Data Warehouse (TRDW): EHR database
containing records from Tufts Medical Center, Tufts Children’s Hospital, and
associated primary and tertiary care clinics fused with oncology data from the Tufts
MC Tumor Registry, and death data from the Massachusetts State Registry of Vital
Records and Statistics. The analysis had institutional review board approval for
using de-identiﬁed data, and thus was determined not to be human subjects
research and informed consent was not deemed necessary.
The Information System for Research in Primary Care (SIDIAP): An EHR
database containing primary care records partially linked to inpatient data
representing 80% of the general population in Spain-Catalonia. The use of SIDIAP
database was approved by the SIDIAP Scientiﬁc Committee and the IDIAPJGol
Clinical Research Ethics Committee.
Health Insurance and Review Assessment COVID database (HIRA COVID): A
national health insurance claims database in South Korea including all patients
who are suspected or conﬁrmed as COVID-19. The analysis had institutional
review board approval for using de-identiﬁed data, and thus was determined not to
be human subjects research and informed consent was not deemed necessary.
Linear mixed model. Due to the heterogeneity of data across sites, the effects of the
covariates on the outcome among sites in the linear regression model may not always
be the same41. Thus, a linear mixed model is often used. With the notations in the
Results section and model in (1), the log-likelihood of LMM using all the data is
1 K
Lðβ; σ2 ; VÞ ¼  ∑ flog jΣi j þ ðyi  X i βÞT Σi 1 ðyi  X i βÞg;
2 i¼1

ð2Þ

where X i and yi are the covariate matrix and the outcome vector of the ith site
respectively, j:jis the matrix determinant and Σi ¼ Σi ðσ 2 ; VÞ ¼ Z i VZ i T þ σ2 I ni :
The maximum likelihood estimation can be further simpliﬁed by proﬁling out β
and σ2 from (2). Denote Θ ¼ V=σ2 . Given Θ, the estimation of β and σ2 are
K
1  K

e
ð3Þ
βðΘÞ ¼ ∑ X i T Γ i 1 Xi
∑ X i T Γ i 1 yi ;
i¼1

e
σ 2 ðΘÞ ¼

i¼1

1 K
∑ ðy  X i e
βðΘÞÞT Γ i 1 ðyi  X i e
βðΘÞÞ;
N i¼1 i

ð4Þ

where Γ i ¼ Γ i ðΘÞ ¼ Z i ΘZ i T þ I ni . Thus, the proﬁle log-likelihood with respect to
only Θ is
1 K
Lp ðΘÞ ¼  ∑ fni log e
βðΘÞÞT Γ i 1 ðyi  X i e
βðΘÞÞg; ð5Þ
σ 2 ðΘÞ þ log jΓ i j þ ðyi  X i e
2 i¼1
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Box 1 | Pseudo-code of the distributed linear mixed model algorithm
1. In site i ¼ 1; :::; K, calculate and share Si X ¼ Xi T Xi , Si Xy ¼ Xi T yi , si y ¼ yi T yi and sample size ni .
2. Perform the likelihood ratio test for the signiﬁcance of random effects of each covariate by Eq. (10).
3. With the signiﬁcant random effects identiﬁed by the above step, reconstruct the proﬁle log-likelihood
^
Equation (5) or the restricted proﬁle log-likelihood Eq. (6), obtain the estimate Θ.
^¼e
^ and σ^2 ¼ e
^ by Eqs. (3) and (4).
4. Obtain β
βðΘÞ
σ 2 ðΘÞ
5. Calculate the variance of the estimated ﬁxed effects ^
β by Eq. (7).
6. Calculates the BLUPs of the random effects in each site by Eq. (11).

^i has mean zero and covariance matrix
Conditioning on X i , u

and the restricted proﬁle log-likelihood is
1 K
ð6Þ
Lr ðΘÞ ¼ Lp ðΘÞ  ∑ flogjX i T Γ i 1 X i j  ni loge
σ 2 ðΘÞg;
2 i¼1
The ML or REML estimate of Θcan be obtained by maximizing (5) or (6). The
estimates of β and σ 2 can be subsequently obtained by (3) and (4). We denote these
^ is
^ Thus, the variance of the estimated ﬁxed effects β
estimates as ð^β; σ^2 ; ΘÞ.
K
1
^ ¼ σ^2 ∑ X T Γ ðΘÞ
^ 1 Xi
ð7Þ
VðβÞ
;
i
i
i¼1

or the sandwich estimator
K
1  K

1
^
^ T Γ ðΘÞ
^ 1 Xi
^ 1 ðy  X i βÞðy
^
βÞ
∑ X i T Γ i ðΘÞ
∑ X i T Γ i ðΘÞ

X
X
i
i
i
i
i
i¼1

Data availability

1

lemma43

ð8Þ

to obtain

jΓ i j ¼ jI q þ Z i T Z i Θj;

ð9Þ

where I q is the q ´ q identity matrix. The proposed DLMM algorithm requires the
ith site to communicate

●

i¼1

We summarize the analysis with the proposed DLMM algorithm as follows,
see Box 1.

i¼1

Γ i 1 ¼ I ni  Z i ðΘ1 þ Z i T Z i Þ Z i T ;

●

"
(
)#
K
1


^
^ 1  σ^2 Γ i ðΘÞ
^ 1 X i ∑ X i T Γ i ðΘÞ
^ 1 Xi
^ 1 Z i Θ:
^ i T σ^2 Γ i ðΘÞ
^i  ui ¼ V  ΘZ
Var u
X i T Γ i ðΘÞ

Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Distributed linear mixed model. It is apparent from (5) that there is no closedform estimation for LMM. Thus, unlike in the ordinary linear model18, LMM
estimation is not trivial as computation cannot be distributed to each site in a
lossless fashion. Fortunately, with some linear algebra, we can disentangle the data
ðyi ; X i Þ and the parameters Θ in jΓ i j and Γ i 1 and thus reconstruct the proﬁle loglikelihood (5) without communicating IPD. Speciﬁcally, we utilize the Woodbury
matrix identity42 to obtain

●

i¼1

Since we are more interested in prediction of ui , it is more appropriate to use
prediction intervals as below

i¼1

K
1
^ 1 Xi
:
∑ X i T Γ i ðΘÞ

and the matrix determinant

"
(
)#
K
1


^ 1  σ^2 Γ i ðΘÞ
^ 1 X i ∑ X i T Γ i ðΘÞ
^ 1 Xi
^ 1 Z i Θ:
^ i T σ^2 Γ i ðΘÞ
^
^i jX i ¼ ΘZ
Var u
X i T Γ i ðΘÞ

p ´ p matrix Si X ¼ X i T X i ;
p  dim vector Si Xy ¼ ðSi yX ÞT ¼ XiT yi ;
scalar si y ¼ yi T yi ; sample size ni ,

Part of the data (aggregated data from CCAE, MDCR, STARR, CUIMC, Optum EHR,
TRDW, SIDIAP, HIRA COVID) are collected by the OHDSI DistributedLMM protocol
(https://github.com/ohdsi-studies/DistributedLMM) and processed by J.R.. Other data
(UHG by M.N.I., OneFlorida by Z.C., Optum COVID by Y.Z.) are processed by the
corresponding co-authors. All the aggregated data are sent to the ﬁrst author (C.L.) for
ﬁnal analysis. The EHR/claims data are proprietary and are not publicly accessible due to
restricted user agreement. The detailed data description and IRB statements of each data
sets are in the Supplementary Notes. For replication purpose, the dataset from the
OneFlorida consortium can be obtained by contacting Dr. Jiang Bian (email:
bianjiang@uﬂ.edu) upon the completion of the data usage agreement.

Code availability
The R code for running DLMM is wrapped in the R (version >= 3.5.0) package “pda”
version 1.0–2, available at CRAN (https://CRAN.R-project.org/package=pda) or github
(https://github.com/Penncil/pda). A separate documentation using simulated data is at
https://github.com/Penncil/DLMM.
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for reconstructing the (restricted) LMM likelihood. Speciﬁcally, to reconstruct (5)
with the above given aggregated data, we plug in (8) to get (3), then plug in (3) to
get (4), then plug in (3), (4) and (9) to get (5). Similarly, the additional terms in (6)
can also be reconstructed by plugging in (8) and (4).
Selection of variance components. We test the signiﬁcance of random effects of
each individual covariate by likelihood ratio test. For simplicity we assume the
potential random effects are independent and the random intercept always exists,
i.e., V ¼ diagðσ 1 2 ; :::; σ q 2 Þ and σ 1 2 > 0. For the covariate corresponding to variance
component σ k 2 ; k ≥ 2, we test
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